Closing the Global Health Gap: Progress Against HIV, TB, and Malaria

By HEOR Staff Writer

August 1, 2023

In the last two decades, the world has seen significant strides in global health, particularly in combating HIV, TB, and malaria. This Oxford study shows that these efforts have not only saved lives but also reduced health inequality and inequity, especially in countries furthest behind.

The article discusses the use of summary indicators of health inequality and inequity to assess improvements in global health outcomes, focusing on HIV, TB, and malaria in fifteen countries in sub-Saharan Africa. The study aims to provide a new perspective on how well health gains benefit countries that are furthest behind in terms of health and economic capacities by using the Gini index and a concentration index ranking countries by gross domestic product (GDP) per capita as indicators of health inequality and inequity.

It was found that from 2002 to 2019, there were significant gains in life expectancy in countries with the lowest life expectancy or low economic development. Inequality in life expectancy across countries declined by one-third during this period, with reduced mortality from HIV, TB, and malaria accounting for half of this gain. The article highlights the importance of considering indicators of health inequality in global health, as it provides valuable insights into health gains.

Reference url

Recent Posts

pharmaceutical access initiative
Pharmaceutical Access Initiative Promotes Unified Health Systems in Europe

By João L. Carapinha

June 12, 2026

The pharmaceutical access initiative led by the Beneluxa countries urges EU and EEA Member States to pursue closer coordination on medicine affordability and supply security. By combining forces, nations can protect universal health systems that treat healthcare as a social right while still enco...
AI Regulatory Research Priorities
AI Regulatory Research Priorities in Medicine Lifecycle Management

By João L. Carapinha

June 12, 2026

AI Regulatory Research Priorities have crystallised around one central requirement: establishing trustworthy performance of artificial intelligence systems across the entire pharmaceutical development and evaluation pathway. Stakeholders from every corner of the European medicines regulatory netw...
gene therapy reimbursement
Gene Therapy Reimbursement Strategies for Vision Restoration

By HEOR Staff Writer

June 12, 2026

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients wit...